• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Beta-blocker therapy in elderly patients with renal dysfunction and heart failure

    2021-03-03 07:32:36JuanMartnezMillaMarcelinoCortGarcJuliaAnnaPalfyMikelTaiboUrquMartapezCastilloAnaDevesaArbiolAnaLucRiveroMonteagudoMarLuisaMartMariscalInJimnezVarasSemBriongosFigueroJuanAntonioFrancoPelaJosTu
    Journal of Geriatric Cardiology 2021年1期
    關(guān)鍵詞:截?cái)嘀?/a>符合率比值

    Juan Martínez-Milla?, Marcelino Cortés García, Julia Anna Palfy, Mikel Taibo Urquía,Marta López Castillo, Ana Devesa Arbiol Ana Lucía Rivero Monteagudo,María Luisa Martín Mariscal, Inés Jiménez-Varas, Sem Briongos Figuero,Juan Antonio Franco-Pelaéz, José Tu?ón,7,8

    1. Department of Cardiology, Hospital Universitario Fundación Jiménez Díaz-Quirónsalud; 2. Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; 3. Department of Cardiology, Hospital Central de Asturias; 4. Department of Cardiology, Hospital Universitario Ruber-Quirónsalud; 5. Department of Cardiology, Hospital Universitario Infanta Leonor; 6. Department of Endocrinology, Hospital Clínico San Carlos; 7. Universidad Autónoma de Madrid; 8. CIBERCV,Madrid, Spain

    ABSTRACT OBJECTIVE To assess the role of beta-blockers (BB) in patients with chronic kidney disease (CKD) aged ≥ 75 years.METHODS AND RESULTS From January 2008 to July 2014, we included 390 consecutive patients ≥ 75 years of age with ejection fraction ≤ 35% and glomerular filtration rate (GFR) ≤ 60 mL/min per 1.73 m2. We analyzed the relationship between treatment with BB and mortality or cardiovascular events. The mean age of our population was 82.6 ± 4.1 years. Mean ejection fraction was 27.9% ± 6.5%. GFR was 60?45 mL/min per 1.73 m2 in 50.3% of patients, 45?30 mL/min per 1.73 m2 in 37.4%, and < 30 mL/min per 1.73 m2 in 12.3%. At the conclusion of follow-up, 67.4% of patients were receiving BB. The median follow-up was 28.04 (IR: 19.41?36.67) months. During the study period, 211 patients (54.1%) died and 257 (65.9%) had a major cardiovascular event (death or hospitalization for heart failure). BB use was significantly associated with a reduced risk of death (HR = 0.51, 95%CI: 0.35?0.74; P < 0.001). Patients receiving BB consistently showed a reduced risk of death across the different stages of CKD:stage IIIa (GFR = 30?45 mL/min per 1.73 m2; HR = 0.47, 95% CI: 0.26?0.86, P < 0.000 1), stage IIIb (GFR 30?45 mL/min per 1.73 m2; HR = 0.55, 95% CI: 0.26?1.06, P = 0.007), and stages IV and V (GFR < 30 mL/min per 1.73 m2; HR = 0.29, 95% CI: 0.11?0.76; P =0.047).CONCLUSIONS The use of BB in elderly patients with HFrEF and renal impairment was associated with a better prognosis.Use of BB should be encouraged when possible.

    Heart failure (HF) is one of the most prevalent cardiovascular (CV) disorders worldwide. Approximately half of all patients with HF have reduced or mid-range ejection fraction.[1,2]Due to their negative inotropic action, for many years beta-blockers (BB) were contraindicated in patients with HF. Toward the end of the last century, however, these drugs were shown to have highly positive effects in patients with HF.Since then, they have become a cornerstone in the treatment of HF with systolic dysfunction,[3]and the most recent clinical practice guidelines encourage BB use to reduce mortality and CV events.[4,5]

    Despite such advances, data remain scarce on the role of these drugs in elderly patients with chronic kidney disease (CKD). Classically, both elderly and CKD patients have been underrepresented in clinical trials, creating a gap in the evidence base. In addition, CKD is highly prevalent among elderly patients with HF and reduced ejection fraction(HFrEF).[6]As a result, though HF drugs (e.g., Angiotensin-Converting Enzyme inhibitors (ACEi)/Angiotensin Receptor Blockers (ARB), BB, Mineralocorticoid Receptor Antagonist (MRA), Angiotensin Receptor-Neprilysin Inhibitors (ARNI))provide a substantial cardiovascular (CV) benefit,the underrepresentation of elderly patients with CKD in the primary clinical trials and the existence of side effects may limit their use.[6,7]As well as ACEi/ARB and MRA,[8]the elderly may be less likely to receive BB than other populations with HFrEF,particularly in cases with associated CKD, despite the fact that there is no clear reason to avoid this medication.[9]Our study analyzes the role of BB therapy in elderly patients with HFrEF and CKD.

    METHODS

    Patients

    We carried out a single-center, observational cohort study. From January 2008 to July 2014, we consecutively enrolled 802 patients 75 years of age or older with left ventricular ejection fraction (LVEF) ≤35% as measured by 2-dimensional echocardiography. Of the total population, 390 had renal impairment, defined as a glomerular filtration rate(GFR) < 60 mL/min per 1.73 m2.

    A specific database compiled in the cardiac imaging department of Hospital Fundación Jiménez Díaz (Madrid, Spain) was used to screen for patients meeting both criteria. All patients underwent regular medical supervision according to their symptoms and the indications of their physician(cardiologists or general practitioners) to optimize treatment.

    This investigation was carried out in accordance with the principles outlined in the Declaration of Helsinki.

    Outcomes and Follow-up

    The outcomes analyzed in our study were the rate of all-cause death and major CV events. Here,CV events included death from any cause or admission due to HF. HF admission was defined as admission to a health-care facility lasting > 24 h due to the worsening of HF symptoms and followed by specific treatment for HF (regardless of the cause of cardiac decompensation). Data on clinical events and death during follow-up were collected from patients’ electronic health records or, if unavailable,from telephone interviews with patients or relatives.

    Statistical Analysis

    Data were subjected to descriptive statistical analysis via frequency measurements (absolute frequencies and percentages) for qualitative variables and using mean and standard deviation for quantitative variables. The magnitude of the effects of the variables was expressed as hazard ratio (HR) and 95% confidence interval (95% CI). Univariate analysis of the quantitative variables was performed using the Student t test when the variables were normally distributed, and the Mann-Whitney U test when distribution was not normal. Qualitative variables were analyzed using the χ2or the Fisher exact test.

    Because observational studies do not allow for randomization, we planned 2 different approaches to avoid potential confounding factors: multivariate Cox proportional hazard and propensity score(PS)-matched analysis. These two analyses were used to determine significant predictors of CV events and mortality. First, we performed a multivariate analysis with Cox (backward stepwise) regression. Of all the baseline variables collected, we selected those with the potential to act as confounding factors. The selection criteria were as follows:first, clinical and biological plausibility and, second,the statistical criterion of Mickey, excluding all those variables that returned a P value > 0.20 on univariate analysis. Second, we performed a PS-matched analysis. The PS was calculated by means of an ordered logistic regression model, taking the BB group as the dependent variables and adopting a parsimonious approach. In a first step, all the following variables were included in the univariate analysis: age, gender, hypertension, diabetes mellitus, obesity, GFR, chronic obstructive pulmonary disease (COPD), peripheral vascular disease, any degree of cognitive impairment, any degree of functional disability, ischemic origin of reduced EF, previous HF admission, sinus rhythm, wide QRS complex, LVEF, and New York Heart Association (NYHA)Class I or II (vs. III, IV, or not available) at initiation of follow-up. All variables with a P-value < 0.2 were entered into a multivariate binary logistic regression model, which served to estimate the PS of every patient. Patient matching was performed at a 1:1 ratio with the nearest neighbor method (caliper =0.2 × SD [logitPs]).

    Results are expressed as hazard ratio (HR) and 95% CI. Statistical analyses were performed with SPSS version 22.0 (SPSS, Inc, Chicago IL, USA).

    RESULTS

    Baseline Characteristics

    During the study period, 802 consecutive patients with LVEF ≤ 35% were assessed for eligibility.Of these, 390 patients were included due to associated renal impairment. Table 1 shows the baseline characteristics of our population. In terms of sex,62.3% were male, and the mean age was 82.6 ± 4.1 years. Mean LVEF was 27.9% ± 6.5%. An ischemic etiology was found in 50.6% of cases. GFR was between 60 and 45 mL/min per 1.73 m2in 50.3% of patients, 45?30 mL/min per 1.73 m2in 37.4%, and <30 mL/min per 1.73 m2in 12.3%.

    At the end of follow-up (32 ± 23 months), 263(67.4%) patients were undergoing treatment with BB. The most commonly used BB by type was bisoprolol once daily in 143 (54.4%) patients followed by carvedilol twice daily in 111 (42.2%) patients,metoprolol twice daily in 6 (2.3%) patients, and nebivolol once daily in 3 (1.1%) patients. Chronic lung disease (32.4%), followed by bradycardia (9.0%), asthenia (4.5%), and deterioration of HF (4.5%) were the most frequent reasons why study subjects did not take BB; however, in 29.7% of these patients no formal contraindication was found. Dose levels of BB used are shown in Table 2 for both the entire population and according to GFR.

    2.3 驗(yàn)證預(yù)測(cè)效果 驗(yàn)證組平均sFlt-1(3 207.79±3 206.82)pg/ml,平均PLGF(729.30±756.96)pg/ml,平均sFlt-1/PLGF(12.87±22.76),取sFlt-1/PLGF比值12.68作為截?cái)嘀?,統(tǒng)計(jì)出驗(yàn)證組的靈敏度為80.0%,特異度為92.6%,符合率為90.6%。

    Outcomes

    After a median follow-up of 28.04 (IR: 19.41?36.67) months, 211 patients (54.1%) died and 257 patients (65.9%) developed a major CV event (death or hospitalization for HF). Of the patients who died,the cause of death was CV in 56 cases (26.5%), and non-CV causes accounted for 73 deaths (34.6%). We were unable to determine the cause of death in 82 patients (38.9%). Regarding HF hospitalization alone, 146 patients (37.4%) of the total study population were admitted due to HF decompensation.We performed a multivariate analysis (Cox regression) of our study population in order to identify significant predictors of total mortality, following the methodology described above. In similar fashion, we performed another multivariate analysis(Cox regression) to determine significant predictors of CV events. Tables 3 and 4 show the results of univariate and multivariate analyses of overall mortality (Table 3) and CV events (Table 4). A multivariate Cox regression analysis revealed that the use of BB was significantly associated with lower mortality rates (HR = 0.53, 95% CI: 0.37?0.78, P logrank < 0.001), as compared with patients not receiving BB (Figure 1A). However, BB use was not significantly associated with differences in CV events.When we used propensity score matching specifically aimed at analyzing the role of BB in our population, we found that BB had benefited our population, producing a difference that reached statistical significance (HR = 0.45, 95% CI: 0.27?0.75, P =0.002) (Figure 1B). Similarly, we found no relationship between BB and CV events. Finally, a multivariate Cox analysis considering HF hospitalization alone revealed no relation between BB and a reduction in HF admissions; only ACEi/ARBs played a protective role in this regard (HR = 0.467; 95%CI: 0.313?0.696).

    When we analyze the role of BB according to eGFR, we see similar results throughout the study population. In the subgroup of patients with stage IIIa CKD (GFR 45?60/min per 1.73 m2), BB significantly reduced mortality (HR = 0.47; 95% CI:0.26?0.86; P log-rank < 0.000 1); the same was true for patients with stage IIIb (GFR = 30?45/min per 1.73 m2; HR = 0.55, 95% CI: 0.26?1.06; P log-rank =0.007) and stages IV and V disease (GFR < 30 mL/min per 1.73 m2; HR = 0.29, 95% CI: 0.11?0.76; P log-rank =0.047) (Figure 2).

    When we analyzed the population by BB dose, no differences in the mean dose of bisoprolol and carvedilol were found between the different glomerular filtration groups. A similar analysis was not done for metoprolol and nebivolol because of their low rate of use in our population.

    Table 1 Baseline characteristics.

    DISCUSSION

    Blocking the adrenergic system with BB has proven effectiveness in patients with HFrEF,[3]and this treatment is currently included in clinical guidelines.[4,5]A closer look at the studies reporting evidence in support of using these drugs, however,reveals that the populations studied present a relatively low number of comorbidities, with few patients over 75 years of age (average age commonly under 65 years),[10,11]making these studies unrepresentative of routine clinical practice.[12]Elderly patients make up a substantial portion of the population with severe left ventricular dysfunction,[9]and the rate of renal failure in this cohort is often 3-fold higher than that of the general population.[13]In addition, these patients have a higher proportion of other comorbidities and polypharmacy, and more than 70% of HF patients older than 80 years fulfil frailty criteria.[14,15]These differences are important to bear in mind when interpreting the results of randomized clinical trials on BB, and nowadays, specific data remain limited and controversial.[16]

    Table 2 Daily doses of beta-blockers used.

    Table 3 Univariate and multivariate analysis of overall mortality.

    Although the available evidence on BB therapy in patients > 70 years with HFrEF is limited, recent studies support the use of these drugs. The SENIORS trial compared the use of BB against a placebo in patients over 70 years of age with HF;[17]all patients included in the study had a clinical history of chronic HF with one or both of the following features: documented hospital admission within the previous 12 months with a discharge diagnosis of congestive HF or documented LVEF ≤ 35% within the previous 6 months. The trial demonstrated a correlation between nebivolol use and a significant(14%) reduction of the primary end-point, a composite of all-cause mortality or cardiovascular hospital admission. Though a secondary end-point, no favorable impact of nebivolol on all-cause mortality was demonstrated (HR = 0.88, 95% CI: 0.71?1.08;P=0.21).[18]We believe that the main difference between the SENIORS study and both our study and pivotal clinical trials is the inclusion of patients with preserved LVEF, since 35% of patients were reported to have LVEF > 35%. In fact, no treatment has demonstrated a clear survival benefit among patients with preserved LVEF-HF.[4,5]There is a lack of robust data evidencing decreased mortality associated with BB administration in the elderly population. Hernandezet al., in the OPTIMIZE-HF registry, suggest that BB are beneficial in elderly patients with HFrEF.[16]Few studies have reported clear benefit of BB in elderly population in terms of mortality. Our group conducted a retrospective, observational study in elderly patients (> 75 years) with HFrEF, concluding that BB therapy improves survival in patients with LVEF lesser than or equal to 0.35, although this effect seems unrelated to the dose received (P= 0.025).[18]

    Table 4 Univariate and multivariate analysis of cardiovascular events.

    Figure 1 All-cause mortality in overall population. (A): Kaplan-Meier curve showing all-cause mortality in the overall population,comparing the group under beta-blocker therapy (green) against the group not receiving this treatment (blue); (B): Kaplan-Meier curve showing all-cause mortality, comparing the group under beta-blocker therapy (green) versus the group that did not use beta-blockers(blue), after propensity score matching.

    Another issue to take into account when evaluating these patients is CKD status. We know this disorder is more prevalent in patients with HF and has an important influence on prognosis.[19,20]In addition, we know that the presence of CKD in HF patients affects the prescription, dosage, and maintenance of therapies that have demonstrated benefits in HFrEF.[4,5]In addition, advanced-stage CKD was an exclusion criterion in many of the clinical trials analyzing the role of BB therapy in patients with HFrEF.[21]Furthermore, those studies that have examined the role of BB therapy in this group of patients are mostly observational in design, and the endpoints used are less relevant (i.e., other than major factors or nonfatal clinical events).[22,23]Despite this lack in the knowledge base, presence of CKD is one of the primary factors associated with increased mortality.[22]

    Most clinical trials carried out to date use exclusion criteria based on glomerular filtration rate(GFR), and as a result patients with Stage I and II kidney disease are well-represented (GFR > 90 mL/min per 1.73 m2and 60?89 mL/min per 1.73 m2, respectively).[24,25]However, this representativeness decreases at lower GFR, and the available data on patients at stage IV and V are scant.

    This pattern can be seen in the classical studies investigating the role of BB therapy in HFrEF patients with associated Stage-IIIa, Stage-IIIb, and Stage-IV-V CKD(25). Although there is no strong evidence of the effect of BB in CKD, stage III is better represented in the different clinical trials. In the MERIT-HF trial (metoprolol vs placebo), which included patients with HFrEF, there was a significant relative risk reduction in the composite endpoint of CV hospitalization/all-cause mortality in patients with GFR of 45?60 mL/min per 1.73 m2(HR = 0.68(0.52?0.90)) and even in patients with GFR < 45 mL/min per 1.73 m2.[26]

    In the CIBIS-II trial on the effect of bisoprolol in patients with HFrEF, BB significantly reduced the mortality and HF-related hospital stay in the subgroup of patients with GFR <60 mL/min per 1.73 m2as well as those with GFR < 45 mL/min per 1.73 m2.[27]As in the SENIORS trial in patients with reduced GFR, the effect of BB was not different from the effect in patients with GFR above 60 mL/min per 1.73 m2.[28]Finally, a meta-analysis of the effect of carvedilol in the COPERNICUS (Carvedilol Prospective Randomized Cumulative Survival) and CAPRICORN (Carvedilol Post Infarct Survival Control in LV Dysfunction) trials showed that this BB significantly improved outcome in patients with eGFR between 45 and 60 mL/min per 1.73 m2.There was no interaction between the effect of carvedilol treatment and eGFR categories (< 45vs.45 to 60 mL/min per 1.73 m2).[29]

    Stages IV and V are not well-represented, though data from both the MERIT-HF and CIBIS-II trials suggest that BB are effective in patients with CKD stage IIIb-V(26,27). Specially, in the MERIT-HF study, the metoprolol/placebo hazard ratio was 0.41 (95% CI: 0.25 to 0.68) in the 493 patients with eGFR < 45 mL/min per 1.73 m2(12% of the whole study population). This subgroup had a mean eGFR of 36.6 ± 6.8 mL/min per 1.73 m2, which included patients with eGFR < 30 mL/min per 1.73 m2.[26]In the SENIORS study, only 3.1% of patients had stage IV CKD, but no subgroup analysis has been performed on these patients.[28]However, only 8% of all patients in these studies had stage 4 CKD. In a small trial of hemodyalisis patients with HF, carvedilol significantly improved the secondary combined endpoint of all-cause mortality and CV death.[30]

    Recently, Kotecha,et al.[31]published the largest meta-analysis including patients with left ventricular dysfunction and CKD. The authors considered 10 double blind placebo-controlled trials that included more than 16,000 patients. They found that BB reduced the relative risk of all-cause mortality by 27% (95% CI: 0.62?0.86) in patients with GFR of 45?60 mL/min per 1.73 m2and 29% (95% CI:0.58?0.87) in those with a GFR of 30?44 mL/min per 1.73 m2. This benefit was only seen in patients in sinus rhythm. In patients with GFR < 30 mL/min per 1.73 m2there were no enough patients to draw conclusions due to the exclusion criteria of the different trials.[31]

    Concern for increased toxicity often leads clinicians to undertreat these patients with CKD, causing less therapeutic resources to be devoted to individuals with myocardial infarction and concomitant CKD.[32]However, it has been shown that these therapeutic measures are beneficial in this population.[33]

    Our population is particularly elderly (mean age,82.6 ± 4.1 years), and as such is representative of the individuals we treat in our daily practice. There is currently no solid evidence on the role of BB in the elderly population with HF and CKD. Given this lack of data about the role of BB in this common population: elderly with HF and CKD. For this reason, we believe that our findings are relevant for overall practice. We found a significant reduction in all-cause mortality, and this benefit was maintained when separately assessing the role of BB treatment in advanced CKD patients (< 45 mL/min per 1.73 m2), as the protective effect of this treatment continues to be statistically significant in terms of all-cause mortality. The effect of treatment with BB is neutral, however, when we isolate the variable of mortality. The high rate of associated cardiovascular co-morbidities may have attenuated the beneficial effect of BB therapy in our study population in terms of CV events.

    In sum, according to our data, treatment with BB in elderly patients presenting HFrEF and CKD was associated with a lower rate of all-cause mortality.Our data thus show that BB therapy could improve the prognosis of this selected population when there is no formal contraindication for its use.

    STUDY LIMITATIONS

    Our study has certain limitations. First, the study population is relatively small, which could influence the statistical results. In addition, it is a retrospective, non-randomized study using a historical cohort from a single center. A third limitation is the relatively short follow-up period, potentially masking a long-term benefit of BB in reduction of CV events. Nevertheless, this last issue is less relevant due to the short life expectancy of elderly patients and the higher number of CV events they present.Lastly, we were unable to discern the cause of death in 82 (38.7%) patients as this information was lacking from their clinical records.

    CONCLUSIONS

    According to our results, use of BB is significantly associated with a reduction in all-cause mortality in elderly patients with HFrEF and CKD irrespective of GFR. As a result, these drugs may be beneficial for these patients provided there are no formal contraindications. Nevertheless, this is an observational study and that residual confounding may exist.

    ACKNOWLEDGMENTS

    To Oliver Shaw for editing the manuscript for aspects related to English language usage and style.

    猜你喜歡
    截?cái)嘀?/a>符合率比值
    ROC曲線在河源市新生兒G6PD缺乏癥篩查截?cái)嘀抵械膽?yīng)用
    中國(guó)實(shí)用醫(yī)藥(2020年24期)2020-09-24 03:10:13
    彩色多普勒超聲檢查在診斷乳腺良惡性腫瘤中的應(yīng)用價(jià)值
    海南省新生兒先天性甲狀腺功能減低癥流行病學(xué)特征及促甲狀腺激素篩查截?cái)嘀档脑O(shè)定
    CT與MRI在宮頸癌分期診斷中的應(yīng)用效果分析
    CT、MRI在眼眶海綿狀血管瘤與眼眶神經(jīng)鞘瘤影像學(xué)鑒別診斷中的研究
    比值遙感蝕變信息提取及閾值確定(插圖)
    河北遙感(2017年2期)2017-08-07 14:49:00
    不同應(yīng)變率比值計(jì)算方法在甲狀腺惡性腫瘤診斷中的應(yīng)用
    論連分?jǐn)?shù)的應(yīng)用
    雙電機(jī)比值聯(lián)動(dòng)控制系統(tǒng)
    久久热在线av| 99精品在免费线老司机午夜| 亚洲人成电影观看| 男女免费视频国产| 黑丝袜美女国产一区| 午夜福利乱码中文字幕| av欧美777| 新久久久久国产一级毛片| 妹子高潮喷水视频| 免费久久久久久久精品成人欧美视频| 大型av网站在线播放| 美女高潮到喷水免费观看| avwww免费| 久久婷婷成人综合色麻豆| 又黄又爽又免费观看的视频| 淫妇啪啪啪对白视频| 夫妻午夜视频| 色综合欧美亚洲国产小说| 午夜福利在线观看吧| 啦啦啦 在线观看视频| 亚洲av成人av| 一a级毛片在线观看| 精品国产超薄肉色丝袜足j| 午夜激情av网站| xxxhd国产人妻xxx| 免费观看精品视频网站| 国产aⅴ精品一区二区三区波| 狂野欧美激情性xxxx| 成人国语在线视频| 一级,二级,三级黄色视频| av有码第一页| 久久中文看片网| 国产男靠女视频免费网站| 亚洲精品成人av观看孕妇| 国产高清视频在线播放一区| 亚洲国产欧美日韩在线播放| 一级毛片高清免费大全| 午夜成年电影在线免费观看| 一区在线观看完整版| 高清毛片免费观看视频网站 | 日本撒尿小便嘘嘘汇集6| 国产成人精品无人区| 女性生殖器流出的白浆| 国产免费av片在线观看野外av| av欧美777| 国产精品久久久av美女十八| 老熟女久久久| 老熟妇乱子伦视频在线观看| 亚洲午夜理论影院| 91大片在线观看| 丰满迷人的少妇在线观看| 777米奇影视久久| 女人精品久久久久毛片| 高清av免费在线| 操出白浆在线播放| 久久久久久久久久久久大奶| 成在线人永久免费视频| 国产男女超爽视频在线观看| 日本黄色日本黄色录像| 亚洲熟妇熟女久久| 亚洲熟妇熟女久久| 免费在线观看完整版高清| 精品视频人人做人人爽| 999久久久精品免费观看国产| 怎么达到女性高潮| 两人在一起打扑克的视频| 99热国产这里只有精品6| 久久午夜亚洲精品久久| 99热国产这里只有精品6| 国产色视频综合| 啪啪无遮挡十八禁网站| 亚洲九九香蕉| 亚洲久久久国产精品| 国产精品香港三级国产av潘金莲| 免费看a级黄色片| 少妇粗大呻吟视频| 精品少妇一区二区三区视频日本电影| 国产成+人综合+亚洲专区| 中文字幕高清在线视频| 黄色a级毛片大全视频| 性色av乱码一区二区三区2| 日本精品一区二区三区蜜桃| 18禁国产床啪视频网站| 国产精品国产av在线观看| av欧美777| 亚洲av成人av| 中文字幕人妻丝袜一区二区| 国产av一区二区精品久久| 国产一区有黄有色的免费视频| 老熟女久久久| 12—13女人毛片做爰片一| 国产亚洲精品久久久久久毛片 | 亚洲国产精品sss在线观看 | 国内久久婷婷六月综合欲色啪| 亚洲一区高清亚洲精品| 久久久水蜜桃国产精品网| 成人国产一区最新在线观看| 老司机深夜福利视频在线观看| 色播在线永久视频| 两人在一起打扑克的视频| 欧美日韩福利视频一区二区| 大香蕉久久成人网| 亚洲黑人精品在线| 叶爱在线成人免费视频播放| 久久香蕉国产精品| 亚洲精品美女久久av网站| 亚洲精品一二三| 久久久国产欧美日韩av| 亚洲av成人不卡在线观看播放网| 丝袜在线中文字幕| 国产又色又爽无遮挡免费看| 亚洲国产精品sss在线观看 | 热re99久久国产66热| 国产aⅴ精品一区二区三区波| 久久人妻av系列| 久久人人爽av亚洲精品天堂| 啦啦啦在线免费观看视频4| 黄色怎么调成土黄色| 亚洲国产中文字幕在线视频| 欧美一级毛片孕妇| 国产成人啪精品午夜网站| 精品一区二区三区av网在线观看| 久久人人爽av亚洲精品天堂| 老司机深夜福利视频在线观看| 91在线观看av| 男男h啪啪无遮挡| 亚洲专区字幕在线| 欧美乱色亚洲激情| 欧美性长视频在线观看| 亚洲欧美日韩另类电影网站| 97人妻天天添夜夜摸| 国产视频一区二区在线看| 777久久人妻少妇嫩草av网站| 国产精品国产高清国产av | 亚洲,欧美精品.| 国产蜜桃级精品一区二区三区 | 高清毛片免费观看视频网站 | 亚洲久久久国产精品| 天堂中文最新版在线下载| 亚洲av熟女| 黄色视频,在线免费观看| 久久人妻熟女aⅴ| 99国产精品免费福利视频| 国产在线观看jvid| 九色亚洲精品在线播放| 成年人午夜在线观看视频| 一边摸一边做爽爽视频免费| 亚洲精品一卡2卡三卡4卡5卡| 亚洲欧美精品综合一区二区三区| 黑人巨大精品欧美一区二区蜜桃| 婷婷精品国产亚洲av在线 | 一夜夜www| 亚洲七黄色美女视频| 黄片大片在线免费观看| 欧美人与性动交α欧美精品济南到| 99精品久久久久人妻精品| 大片电影免费在线观看免费| 午夜免费鲁丝| 黄色怎么调成土黄色| 亚洲av成人一区二区三| 成人永久免费在线观看视频| 超碰成人久久| av电影中文网址| 高清欧美精品videossex| 国产精品乱码一区二三区的特点 | 另类亚洲欧美激情| 久久精品国产清高在天天线| 人妻一区二区av| 国产午夜精品久久久久久| 露出奶头的视频| 国产男女超爽视频在线观看| 中文字幕人妻丝袜制服| 国产精品久久久久久人妻精品电影| 午夜亚洲福利在线播放| 亚洲一码二码三码区别大吗| 91国产中文字幕| 亚洲人成伊人成综合网2020| 中文字幕色久视频| 怎么达到女性高潮| 91九色精品人成在线观看| 精品福利观看| 国产高清视频在线播放一区| 国产一区有黄有色的免费视频| 国产免费av片在线观看野外av| 国产精品免费大片| 黄色视频,在线免费观看| 日本a在线网址| 电影成人av| 亚洲人成电影免费在线| 首页视频小说图片口味搜索| 欧美另类亚洲清纯唯美| 午夜福利在线观看吧| 男女之事视频高清在线观看| 免费看十八禁软件| 国产国语露脸激情在线看| 亚洲欧美激情综合另类| av天堂久久9| 久久精品国产综合久久久| 一级a爱视频在线免费观看| 午夜精品国产一区二区电影| av在线播放免费不卡| 女人久久www免费人成看片| 国产亚洲精品久久久久5区| 国产精品偷伦视频观看了| 中文字幕色久视频| 真人做人爱边吃奶动态| 午夜91福利影院| 亚洲中文字幕日韩| 妹子高潮喷水视频| 在线观看免费视频网站a站| 亚洲精品粉嫩美女一区| 最近最新中文字幕大全免费视频| 免费观看a级毛片全部| 女人精品久久久久毛片| svipshipincom国产片| 国产精品电影一区二区三区 | 91麻豆精品激情在线观看国产| 亚洲熟妇熟女久久| 中亚洲国语对白在线视频| 51国产日韩欧美| 亚洲人成网站高清观看| 中文亚洲av片在线观看爽| 国产真实伦视频高清在线观看 | 精品99又大又爽又粗少妇毛片 | 91久久精品电影网| 99久久久亚洲精品蜜臀av| eeuss影院久久| 久久久久久国产a免费观看| 69av精品久久久久久| 中文字幕精品亚洲无线码一区| 国产伦精品一区二区三区四那| a级一级毛片免费在线观看| av天堂中文字幕网| 国产精品久久久久久亚洲av鲁大| 日韩欧美一区二区三区在线观看| 琪琪午夜伦伦电影理论片6080| 狠狠狠狠99中文字幕| 精品欧美国产一区二区三| 色综合欧美亚洲国产小说| 亚洲在线自拍视频| 国产精品99久久久久久久久| 亚洲人成网站在线播放欧美日韩| 99国产极品粉嫩在线观看| 草草在线视频免费看| 亚洲国产欧美人成| 日本a在线网址| 97超级碰碰碰精品色视频在线观看| 国产综合懂色| 天天一区二区日本电影三级| 女人高潮潮喷娇喘18禁视频| 亚洲无线在线观看| 日韩欧美精品免费久久 | 91在线精品国自产拍蜜月 | 一区二区三区激情视频| 亚洲自拍偷在线| 国产精品女同一区二区软件 | 黄色女人牲交| 舔av片在线| 最近在线观看免费完整版| 国产综合懂色| 白带黄色成豆腐渣| 波多野结衣高清无吗| 99精品欧美一区二区三区四区| 国产伦人伦偷精品视频| e午夜精品久久久久久久| 国产伦精品一区二区三区四那| 亚洲欧美日韩东京热| 亚洲av成人不卡在线观看播放网| 国产av不卡久久| 桃红色精品国产亚洲av| 成人18禁在线播放| 国产精品99久久久久久久久| 欧美一区二区精品小视频在线| 日本精品一区二区三区蜜桃| 午夜精品在线福利| 欧美成人免费av一区二区三区| 国产av麻豆久久久久久久| 婷婷精品国产亚洲av| 久久国产乱子伦精品免费另类| 亚洲熟妇熟女久久| 久久精品91无色码中文字幕| 最新在线观看一区二区三区| 亚洲在线自拍视频| 老熟妇乱子伦视频在线观看| 此物有八面人人有两片| 宅男免费午夜| 亚洲七黄色美女视频| 午夜激情福利司机影院| 高清在线国产一区| 成人永久免费在线观看视频| 91久久精品电影网| 国产成人福利小说| 中国美女看黄片| 亚洲av不卡在线观看| 91九色精品人成在线观看| 国产三级中文精品| 亚洲国产欧洲综合997久久,| 俺也久久电影网| 在线播放国产精品三级| 国内精品一区二区在线观看| 午夜影院日韩av| 99精品在免费线老司机午夜| 99久久久亚洲精品蜜臀av| 俄罗斯特黄特色一大片| 国产视频内射| 18+在线观看网站| 12—13女人毛片做爰片一| 18禁国产床啪视频网站| 亚洲欧美日韩卡通动漫| 成人鲁丝片一二三区免费| 在线国产一区二区在线| 成人国产一区最新在线观看| 午夜免费观看网址| 久99久视频精品免费| 一级毛片女人18水好多| 国产99白浆流出| 亚洲国产欧洲综合997久久,| 最后的刺客免费高清国语| 久久伊人香网站| 日韩国内少妇激情av| 搡老岳熟女国产| 欧美一区二区亚洲| 很黄的视频免费| 在线播放无遮挡| 最好的美女福利视频网| 九色成人免费人妻av| 亚洲国产色片| 淫妇啪啪啪对白视频| 不卡一级毛片| 香蕉av资源在线| 99久久无色码亚洲精品果冻| 亚洲av不卡在线观看| 欧美日韩精品网址| avwww免费| 啪啪无遮挡十八禁网站| 精品人妻一区二区三区麻豆 | 日韩亚洲欧美综合| 国产久久久一区二区三区| 亚洲欧美日韩东京热| 成人三级黄色视频| 99久久无色码亚洲精品果冻| 亚洲avbb在线观看| 搞女人的毛片| 五月伊人婷婷丁香| 最近最新中文字幕大全免费视频| 精品午夜福利视频在线观看一区| 欧美日韩瑟瑟在线播放| 一a级毛片在线观看| 男女视频在线观看网站免费| 日韩欧美国产在线观看| 老汉色∧v一级毛片| 男女床上黄色一级片免费看| 免费观看的影片在线观看| 国产 一区 欧美 日韩| 成年版毛片免费区| 日本 av在线| 嫩草影院入口| 色尼玛亚洲综合影院| 国产精品99久久99久久久不卡| 一区福利在线观看| 久久亚洲真实| 国内久久婷婷六月综合欲色啪| h日本视频在线播放| 午夜免费观看网址| 亚洲精品久久国产高清桃花| 国产精品 欧美亚洲| 在线观看免费视频日本深夜| 亚洲精品色激情综合| 久久性视频一级片| 人妻丰满熟妇av一区二区三区| 亚洲精品一区av在线观看| 久久精品91无色码中文字幕| 国产av一区在线观看免费| 欧美日韩综合久久久久久 | 亚洲av成人av| 欧美3d第一页| 欧美日韩国产亚洲二区| 国产蜜桃级精品一区二区三区| 一边摸一边抽搐一进一小说| 色综合欧美亚洲国产小说| 欧美日韩精品网址| 亚洲激情在线av| 日韩亚洲欧美综合| 国产激情欧美一区二区| 日本五十路高清| 狠狠狠狠99中文字幕| 精品久久久久久久久久久久久| 人妻夜夜爽99麻豆av| 免费观看人在逋| 少妇的丰满在线观看| 欧美日韩瑟瑟在线播放| 久久亚洲精品不卡| 一边摸一边抽搐一进一小说| 国产综合懂色| 国内精品美女久久久久久| 国产亚洲欧美在线一区二区| 操出白浆在线播放| 欧美乱码精品一区二区三区| av国产免费在线观看| 久久天躁狠狠躁夜夜2o2o| 午夜久久久久精精品| 国产99白浆流出| 国产一区二区亚洲精品在线观看| 欧美日韩福利视频一区二区| 9191精品国产免费久久| 久久国产乱子伦精品免费另类| 99国产精品一区二区蜜桃av| 国产高清videossex| 亚洲中文字幕一区二区三区有码在线看| 男女床上黄色一级片免费看| 最近在线观看免费完整版| 一级毛片高清免费大全| 色在线成人网| 一边摸一边抽搐一进一小说| 中文字幕av在线有码专区| 亚洲成人精品中文字幕电影| 久久天躁狠狠躁夜夜2o2o| 成人一区二区视频在线观看| 男人舔奶头视频| 亚洲aⅴ乱码一区二区在线播放| 制服人妻中文乱码| 神马国产精品三级电影在线观看| 亚洲七黄色美女视频| 精品99又大又爽又粗少妇毛片 | 国产精品久久久久久人妻精品电影| 午夜精品一区二区三区免费看| 久久欧美精品欧美久久欧美| 欧美日韩乱码在线| 国产综合懂色| 亚洲精品在线观看二区| 人人妻人人看人人澡| 成人特级黄色片久久久久久久| 有码 亚洲区| 老司机福利观看| 成年女人看的毛片在线观看| 午夜福利免费观看在线| 亚洲av不卡在线观看| 亚洲成人久久性| 女人十人毛片免费观看3o分钟| 啦啦啦观看免费观看视频高清| 午夜福利在线在线| 十八禁人妻一区二区| 欧美乱码精品一区二区三区| 精品国产三级普通话版| 亚洲欧美日韩高清专用| 国产黄片美女视频| 有码 亚洲区| 少妇人妻精品综合一区二区 | 亚洲成人免费电影在线观看| 99在线人妻在线中文字幕| xxxwww97欧美| 国产一区二区三区视频了| 男女之事视频高清在线观看| 国产真实伦视频高清在线观看 | 亚洲国产日韩欧美精品在线观看 | 日本一本二区三区精品| 少妇丰满av| 一本一本综合久久| 欧美+日韩+精品| 97超视频在线观看视频| 欧美3d第一页| 亚洲中文字幕日韩| 天天添夜夜摸| 色尼玛亚洲综合影院| 91字幕亚洲| 中亚洲国语对白在线视频| 亚洲成av人片在线播放无| 丰满人妻一区二区三区视频av | 天堂影院成人在线观看| 午夜免费成人在线视频| 嫁个100分男人电影在线观看| 午夜视频国产福利| 久久婷婷人人爽人人干人人爱| 国产淫片久久久久久久久 | 欧美另类亚洲清纯唯美| 日韩免费av在线播放| 最后的刺客免费高清国语| 一本综合久久免费| 国产精品一及| 亚洲精品456在线播放app | 久久久色成人| 国产乱人伦免费视频| 深爱激情五月婷婷| 免费观看精品视频网站| www.色视频.com| 久久久国产成人精品二区| 久久久久久九九精品二区国产| 日本 欧美在线| 亚洲成av人片在线播放无| 国产私拍福利视频在线观看| 国产精品亚洲av一区麻豆| 色哟哟哟哟哟哟| 一个人观看的视频www高清免费观看| 久久久久久久亚洲中文字幕 | 精品一区二区三区人妻视频| 18禁美女被吸乳视频| 中文字幕久久专区| 亚洲精品在线观看二区| 日本一二三区视频观看| 国产免费男女视频| 亚洲内射少妇av| 国产综合懂色| 国产野战对白在线观看| 给我免费播放毛片高清在线观看| 国产精品国产高清国产av| or卡值多少钱| 亚洲在线观看片| 婷婷六月久久综合丁香| 亚洲一区高清亚洲精品| 日本免费一区二区三区高清不卡| 一本久久中文字幕| 激情在线观看视频在线高清| 淫秽高清视频在线观看| 波多野结衣巨乳人妻| 亚洲激情在线av| av片东京热男人的天堂| 成人特级黄色片久久久久久久| 欧美zozozo另类| 亚洲一区二区三区不卡视频| 有码 亚洲区| 制服人妻中文乱码| 亚洲精品成人久久久久久| 国产麻豆成人av免费视频| 亚洲中文字幕一区二区三区有码在线看| 18美女黄网站色大片免费观看| 99国产精品一区二区三区| 久久久久久久午夜电影| 真实男女啪啪啪动态图| 中文字幕人成人乱码亚洲影| 日本撒尿小便嘘嘘汇集6| 国产免费一级a男人的天堂| 色精品久久人妻99蜜桃| 日韩国内少妇激情av| 国产精品自产拍在线观看55亚洲| 免费在线观看日本一区| 日韩欧美三级三区| 国产高清videossex| 丰满的人妻完整版| 少妇的丰满在线观看| 精品电影一区二区在线| 欧美色视频一区免费| 久久香蕉精品热| 亚洲精品影视一区二区三区av| 一个人看视频在线观看www免费 | 色综合欧美亚洲国产小说| 国产男靠女视频免费网站| 黄色片一级片一级黄色片| 国产高清视频在线播放一区| 麻豆国产av国片精品| 夜夜看夜夜爽夜夜摸| 母亲3免费完整高清在线观看| 一个人看视频在线观看www免费 | 精品久久久久久久久久免费视频| www.色视频.com| 欧美国产日韩亚洲一区| 亚洲精品成人久久久久久| 日本黄色片子视频| 波多野结衣高清无吗| 日韩有码中文字幕| 日韩欧美 国产精品| 欧美乱妇无乱码| 亚洲精品在线美女| 亚洲国产色片| 白带黄色成豆腐渣| 深夜精品福利| 法律面前人人平等表现在哪些方面| 日本五十路高清| 久久久久国内视频| 成人高潮视频无遮挡免费网站| 制服丝袜大香蕉在线| 久久久久亚洲av毛片大全| 久9热在线精品视频| 精品国产超薄肉色丝袜足j| 久久性视频一级片| 亚洲国产高清在线一区二区三| 桃红色精品国产亚洲av| 男插女下体视频免费在线播放| 国产熟女xx| 嫩草影院精品99| 国产伦一二天堂av在线观看| 国产精品精品国产色婷婷| 久久精品亚洲精品国产色婷小说| 日韩欧美免费精品| 一个人看视频在线观看www免费 | 老师上课跳d突然被开到最大视频 久久午夜综合久久蜜桃 | 夜夜看夜夜爽夜夜摸| 精品免费久久久久久久清纯| 天天一区二区日本电影三级| 最近最新中文字幕大全免费视频| 丁香六月欧美| 久久久久久大精品| 91在线观看av| 欧美性猛交╳xxx乱大交人| 欧美+日韩+精品| 一个人免费在线观看电影| 免费看光身美女| 啪啪无遮挡十八禁网站| 成年版毛片免费区| 一边摸一边抽搐一进一小说| 一区二区三区激情视频| 男人和女人高潮做爰伦理| 精品一区二区三区人妻视频| 麻豆国产av国片精品| ponron亚洲| 精品无人区乱码1区二区| 午夜影院日韩av| 精品日产1卡2卡| 九九久久精品国产亚洲av麻豆| 欧美中文综合在线视频| 色吧在线观看| 欧美一级a爱片免费观看看| 丰满乱子伦码专区| 欧美乱码精品一区二区三区| 亚洲七黄色美女视频| 少妇高潮的动态图|